Wegovy vs Ozempic: Same Molecule, Genuinely Different Rules
Wegovy and Ozempic are both semaglutide from Novo Nordisk - the confusion is understandable. But the maximum approved dose, the FDA-approved indication, the insurance-coverage path, and the self-pay economics are genuinely different, not just marketing labels on identical products. If you don't have type 2 diabetes, this distinction can cost you real money. Here's the honest breakdown.
Weight loss comparison (220 lbs starting weight)
% of body weight lost over 18 months, modeled from phase 3 trial data
Monthly cost by payment channel
| Channel | Wegovy | Ozempic |
|---|---|---|
| Insurance copay (typical) | $63 | $63 |
| Manufacturer self-pay | $349 | - |
| Branded telehealth | $329 | $399 |
| Compounded (limited availability) | $249 | $199 |
| Cash retail (full WAC) | $1,349 | $998 |
Note the WAC list price paradox: Ozempic's sticker price ($998/mo) is actually LOWER than Wegovy's ($1,349/mo) - but without a self-pay program, most cash-pay patients never see that lower list price reflected in what they actually pay.
Which one should you actually be on?
Choose Wegovy if:your primary goal is weight loss and you don't have type 2 diabetes, you want access to the higher 2.4 mg ceiling dose, or you want NovoCare self-pay pricing if insurance denies you.
Choose Ozempic if:you have type 2 diabetes and your insurance covers it (T2D coverage rates for Ozempic are typically higher than weight-loss coverage rates for Wegovy), or your prescriber has specific cardiovascular risk-reduction reasons tied to Ozempic's SUSTAIN-6 data.
Talk to your prescriber if:you have diabetes AND weight loss is now your primary goal - moving to Wegovy's higher dose ceiling is a legitimate conversation once glucose control is stable, not something unusual to ask about.
Where to actually buy Wegovy or Ozempic (and the alternatives)
Manufacturer direct prices (LillyDirect, NovoCare) are usually cheapest. Updated May 2026.
| Drug | Insurance | Mfr direct | Telehealth (brand) | Telehealth (compd) | Cash retail | Get it |
|---|---|---|---|---|---|---|
| Wegovy 14.9% weight loss | $63 | $349 | $329 | $249 cheapest | $1,349 | Get →ad |
| Ozempic 11.6% weight loss | $63 | - | $399 | $199 cheapest | $998 | Get →ad |
| Wegovy (oral 25mg) 13.6% weight loss | $63 | $149 cheapest | $449 | - | $1,349 | Get →ad |
| Zepbound 22.5% weight loss | $88 | $299 cheapest | $499 | $299 cheapest | $1,059 | Get →ad |
| Mounjaro 20.9% weight loss | $88 | - | $499 | $299 cheapest | $1,069 | Get →ad |
| Saxenda 8.4% weight loss | $63 | - | $399 cheapest | - | $1,349 | Get →ad |
| Foundayo (orforglipron) 14.7% weight loss | $63 | $149 cheapest | - | - | $1,099 | Get →ad |
Frequently asked questions
Is Wegovy literally the same drug as Ozempic?
The active ingredient is identical - both are semaglutide, made by Novo Nordisk. What differs is the FDA-approved indication and the maximum dose. Wegovy is approved for chronic weight management and titrates up to a 2.4 mg maintenance dose. Ozempic is approved for type 2 diabetes (plus cardiovascular risk reduction in T2D patients) and tops out at 2.0 mg. Same molecule, same injection pen technology, different regulatory pathway and a meaningfully different ceiling dose - which is why Wegovy's STEP-1 trial showed 14.9% peak weight loss versus Ozempic's roughly 11.6% in comparable weight-loss-focused analyses.
Why would a doctor prescribe Ozempic for weight loss instead of Wegovy?
Almost always for insurance-coverage reasons, not clinical ones. If a patient has type 2 diabetes, prescribing Ozempic (the on-label diabetes drug) is far more likely to clear insurance prior authorization than prescribing Wegovy off-label, even when the actual clinical goal is weight loss. This is a real and common pattern - some prescribers specifically choose Ozempic for patients with borderline glucose numbers because it is easier to justify to an insurer, understanding the patient will get somewhat less weight loss at the lower 2.0 mg ceiling than they would on Wegovy.
If I do not have diabetes, can I still get prescribed Ozempic?
Legally yes - off-label prescribing is standard medical practice and doctors can prescribe Ozempic for weight loss without a diabetes diagnosis. Practically, insurance will not cover it without the diabetes indication, so you would be cash-pay on Ozempic with no manufacturer self-pay program (NovoCare's self-pay pricing runs through Wegovy, not Ozempic) - meaning you would likely pay MORE for the same molecule at a LOWER maximum dose than if you simply got prescribed Wegovy instead. There is essentially no scenario where a non-diabetic cash-pay patient should choose Ozempic over Wegovy.
What is the actual cost difference for a non-diabetic patient?
Meaningful. Wegovy NovoCare self-pay runs around $349/mo. Ozempic has no self-pay program - branded telehealth runs around $399/mo, meaningfully higher than Wegovy's self-pay floor, for a lower maximum dose and correspondingly less weight loss. If cost is the driving factor and you don't have diabetes, Wegovy wins on essentially every axis: lower self-pay price, higher ceiling dose, more weight loss, and the on-label indication that matches your actual goal.
Does the Ozempic savings card work for weight loss prescriptions?
No. The Ozempic Savings Card from Novo Nordisk requires an active type 2 diabetes prescription on file with commercial insurance coverage - it will not activate on an off-label weight-loss prescription, even if your insurer technically covers Ozempic for something else. This is a hard eligibility gate, not a technicality you can work around.
I am already on Ozempic for diabetes - should I switch to Wegovy for more weight loss?
Discuss it with your prescriber rather than deciding alone. The clinical case for staying on Ozempic if you have type 2 diabetes: insurance coverage is typically more reliable, and Ozempic carries specific cardiovascular outcome data (SUSTAIN-6) for diabetic patients that Wegovy's trials didn't specifically target. The case for switching to Wegovy: the higher 2.4 mg ceiling dose produces more weight loss for patients where that is the primary goal, and if you can maintain insurance coverage or afford NovoCare self-pay, there's no clinical reason to stay capped at 2.0 mg. Many patients with both diabetes and a weight-loss goal end up on Wegovy once their diabetes is well-controlled and weight loss becomes the primary treatment target - that's a conversation for your endocrinologist or PCP, not a self-directed switch.
Is compounded semaglutide the same regardless of whether I ask for "Ozempic" or "Wegovy" dosing?
Compounded semaglutide is priced and dosed by the pharmacy, not the brand name - a 503A pharmacy filling compounded semaglutide isn't making "Ozempic" or "Wegovy," it's making semaglutide at whatever dose your prescriber specifies. Availability narrowed sharply after the FDA closed the shortage-based compounding pipeline in 2024-2025; where a pharmacy still fills case-by-case (roughly $199/mo), the "which brand" distinction is largely irrelevant - what matters is the dose your prescriber writes and the pharmacy's licensing/accreditation.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.